# What a breast cancer cell experiment tested with a growth hormone fragment

- Article ID: research-118
- Product: Fragment 176-191 (fragment-176-191-435)
- Canonical page: https://heritagebiolabs.com/research-library/articles/118-what-a-breast-cancer-cell-experiment-tested-with-a-growth-hormone-fragment
- Product collection: https://heritagebiolabs.com/research-library/products/fragment-176-191
- Product page: https://heritagebiolabs.com/product/fragment-176-191-435
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 1986, 2022, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides consist of short amino-acid chains held together by peptide bonds. A peptide can be included in an experimental carrier to study how that carrier interacts with a cell. Fragment 176–191 refers to a sequence near the end of mature human growth hormone. An older study used a material labeled hGH Fragment 176–191 together with doxorubicin in a particle and tested whether the two-material particle changed the viability of cultured breast cancer cells. [1, 2]

The carrier was made from chitosan, a sugar-based polymer. The investigators compared particles containing the chemotherapy drug doxorubicin with particles carrying doxorubicin and the peptide. They also ran computer simulations of how the peptide and drug might fit against certain proteins. Docking simulations can suggest interactions to test, while a cell experiment can show whether a measured response changes under specified laboratory conditions. [1]

In the cell experiment, the dual-loaded particles produced greater inhibition of cell growth than the doxorubicin-loaded particles. The study used the MCF-7 human breast cancer cell line. “Human” in this context identifies where the cell line originated. The study did not test the particles in people or measure whether the drug reached a tumor inside the body. The result also belongs to a particular nanoparticle containing both materials. [1]

The experiment is an example of evidence about a delivery system. To interpret it, the reader needs to know what the carrier held, what it was compared against and where the comparison was performed. It provides no direct measure of the isolated fragment’s effect in patients. It also addresses a different research question from the older experiments on blood sugar or fat metabolism. [1]

## Sources

1. M. M. Habibullah et al. Human Growth Hormone Fragment 176–191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Design, Development and Therapy (publication 2022-06-27). <https://pubmed.ncbi.nlm.nih.gov/35783198/>
2. UniProt Consortium. GH1 - Somatotropin - Homo sapiens (Human). UniProtKB P01241 (publication 1986-07-21, record updated 2026-11-04). <https://www.uniprot.org/uniprotkb/P01241/entry>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 024 - Fragment 176-191.docx; article 118; content SHA-256 ee8d8d810a6cd8f1ef19ffe42fa40298fc9133f1266abc5cfb74424bf43957f0.
